Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06171685 · ClinicalTrials.gov registry record · Phase 2
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
A Phase 2 study of Refractory Multiple Myeloma and Relapse Multiple Myeloma, sponsored by Multiple Myeloma Research Consortium.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 13
- Study locations
NCT06171685 is a Phase 2 study of Refractory Multiple Myeloma and Relapse Multiple Myeloma that is actively recruiting participants, run by Multiple Myeloma Research Consortium. The registered enrollment target is 300 participants, above the 44-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (582% higher). The trial reports 13 study locations across 11 states.
The verdict
NCT06171685, a Phase 2 study of Refractory Multiple Myeloma and Relapse Multiple Myeloma, is actively recruiting participants, sponsored by Multiple Myeloma Research Consortium.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 13
- Study locations
Study Summary
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready and whether accrual in the trial will support another arm. Accrual to an arm will terminate in accord with the arm's appendix to the Master Protocol. The purpose of this proposed structure is to support the recurrent research challenge of efficiently evaluating what is the best therapy for a particular patient.
Conditions Studied
Interventions
- DRUG Teclistamab Monotherapy
- DRUG Teclistamab
Study Locations (13)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute/Harvard Medical School - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
- Mt. Sinai School of Medicine - New York
California
- City of Hope - Duarte
Georgia
- Emory Winship Cancer Center - Atlanta
Illinois
- University of Chicago Cancer Center - Chicago
Michigan
- Barbara Ann Karmanos Cancer Center - Detroit
Minnesota
- Mayo Clinic Rochester - Rochester
Missouri
- Washington University Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-11-17 |
| Est. Completion | 2030-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06171685
The ClinicalTrials.gov registry entry for NCT06171685 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 44-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (582% higher). The listed sponsor is Multiple Myeloma Research Consortium, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractory Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Teclistamab Monotherapy is the first listed.
NCT06171685 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Massachusetts, New York, California.
Frequently Asked Questions
What is clinical trial NCT06171685 about?
NCT06171685 is a clinical study titled "MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM". This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether th...
What is the current status of trial NCT06171685?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2024-11-17. Estimated completion is 2030-07-31.
What conditions does trial NCT06171685 study?
This clinical trial studies the following conditions: Refractory Multiple Myeloma, Relapse Multiple Myeloma.
What interventions are being tested in trial NCT06171685?
The interventions under investigation include: Teclistamab Monotherapy (DRUG), Teclistamab (DRUG).
Who is sponsoring clinical trial NCT06171685?
This trial is sponsored by Multiple Myeloma Research Consortium, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06171685 being conducted?
This trial has 13 study locations across California, Georgia, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
-
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
RECRUITING · Phase 2
-
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
RECRUITING · Phase 2
-
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.